National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
|Podcasts|September 14, 2011
Treating Prodromal Symptoms of Psychosis
Author(s)Irene M. Hurford, MD
Listen
0:00 / 0:00
A review of some of the latest study findings on the pharmacological treatment of prodromal psychosis.
Advertisement
What are the pros and cons of treating subtreshold high-risk psychotic symptoms? Does early intervention help or hinder patient outcomes? Can conversion to psychosis be delayed or prevented? Dr Hurford reviews some of the latest study findings on the pharmacological treatment of prodromal psychosis.
Dr Hurford is Assistant Professor in the Department of Psychiatry at the University of Pennsylvania.
Treating Prodromal Symptoms of Psychosis
Advertisement
Related to this article
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Brain Trust: Bessel van der Kolk, MD, on Complex PTSD, Attachment, and the Limits of Pharmacotherapy
3
Podcast: Campus Naloxone Access and Destigmatizing Substance Use Disorders
4
Artificial Intelligence in Psychiatric Clinical Trials: Opportunities and Limitations
5